机译:Peginterferonα的长期随访甲基阳性慢性乙型肝炎患者的PEGINTERENSON-2B(40KD,Y形)(Pegberon)研究
Peking Univ Hosp 1 Beijing Peoples R China;
Henan Prov Peoples Hosp Zhenzhou Peoples R China;
Sixth Peoples Hosp Shenyang Shenyang Liaoning Peoples R China;
Fuzhou Infect Dis Hosp Fuzhou Fujian Peoples R China;
Peking Univ Shenzhen Hosp Shenzhen Peoples R China;
Jinan Infect Dis Hosp Jinan Shandong Peoples R China;
Chongqing Med Univ Affiliated Hosp 2 Chongqing Peoples R China;
Southeast Univ Affiliated Hosp 2 Nanjing Jiangsu Peoples R China;
Xiamen Hosp TCM Xiamen Peoples R China;
Third Mil Med Univ Southeast Hosp Chongqing Peoples R China;
Wenzhou Med Univ Affiliated Hosp 1 Wenzhou Peoples R China;
Peoples Liberat Army Hosp 81 Nanjing Jiangsu Peoples R China;
Guangzhou Eighth Peoples Hosp Guangzhou Guangdong Peoples R China;
Southern Med Univ Nangfang Hosp Guangzhou Guangdong Peoples R China;
Peking Univ Peoples Hosp Beijing Peoples R China;
Captial Med Univ Beijing Youan Hosp Beijing Peoples R China;
Cent S Univ Xiangya Hosp Changsha Hunan Peoples R China;
Xiamen Amoytop Biotech Co Ltd Xiamen Peoples R China;
Peking Univ Hosp 1 Beijing Peoples R China;
机译:Peginterferonα的长期随访甲基阳性慢性乙型肝炎患者的PEGINTERENSON-2B(40KD,Y形)(Pegberon)研究
机译:聚乙二醇干扰素α-2b治疗期间早期HBeAg丢失可预测HBsAg丢失:这是对慢性乙型肝炎患者进行的长期随访研究的结果。
机译:II期和III期研究对聚乙二醇干扰素α-2a治疗乙型肝炎e抗原(HBeAg)阳性和HBeAg阴性的慢性乙型肝炎患者的长期随访
机译:HCV相关因素但基线上没有艾滋病毒相关因素预测与HCV / HIV共感染患者的Peginterferon Alfa-2a(40kd)(Pegasys)(Pegasys)加利巴韦林(Copegus)对治疗的反应:来自杏研究的预测因素分析
机译:Peginterferon Alpha-2a与Peginterferon Alpha-2b在单纯性慢性HCV基因型4患者中的治疗效果:单中心埃及研究
机译:PGI1联合应用Peginterferon Alpha-2a或Alpha-2b和利巴韦林治疗丙型肝炎的有效性和耐受性:基于日本全国肝炎注册的结果